Alexis Yongmei Ji
Venture investor @ Life Science Venture Capital Management
San Francisco, United States
Alexis Yongmei Ji is a Venture investor at Life Science Venture Capital.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Alexis Yongmei Ji invests in
Stages Alexis Yongmei Ji invests in
Countries Alexis Yongmei Ji invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (50%)
- Medical Device 2 (33%)
- Medical 1 (17%)
- Oncology 1 (17%)
- Health Care 1 (17%)
Stage
- Series A 2 (33%)
- Series B 1 (17%)
- Series C 1 (17%)
- Series D 1 (17%)
- Funding Round 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Walking Fish Therapeutics
|
Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies. | $50M / Series A / Sep 13, 2021 | |
NanoCellect Biomedical
|
NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.A critical element for biomedical research is the ability for scientists to analyze and isolate cellsusing flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research. | $20M / Series D / Aug 13, 2021 | |
|
NanoCellect Biomedical
|
NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.A critical element for biomedical research is the ability for scientists to analyze and isolate cellsusing flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research. | $15M / Series C / Feb 01, 2021 | |
Actym Therapeutics, Inc.
|
Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies,STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy.In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures. | $34M / Series A / Apr 27, 2020 | |
|
NanoCellect Biomedical
|
NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.A critical element for biomedical research is the ability for scientists to analyze and isolate cellsusing flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research. | $250K / Jan 12, 2018 | |
|
NanoCellect Biomedical
|
NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.A critical element for biomedical research is the ability for scientists to analyze and isolate cellsusing flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research. | $10M / Series B / Nov 29, 2017 |
Co-Investors
Life Science Venture Capital Management
Life Science Venture Capital Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alexis Yongmei Ji
Venture investor
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexis Yongmei Ji invest in?
Alexis Yongmei Ji invests primarily in Biotechnology, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexis Yongmei Ji?
Public channels for Alexis Yongmei Ji include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alexis Yongmei Ji last invest?
The most recent investment recorded for Alexis Yongmei Ji closed in Sep 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
